Described are receptor ligands of transient receptor potential cation channel subfamily V member 4 (TRPV4), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ocular disorders.

Treatments for cancer include miriplatin assembled into an ultra-small dot (uPtD) and/or lomitapide or a pharmaceutically-acceptable salt thereof. The uPtD and/or lomitapide can be encapsulated in a nanoparticle for administration to a subject. Some embodiments further include paclitaxel or a pharmaceutically-acceptable salt thereof.

Treatments for cancer include miriplatin assembled into an ultra-small dot (uPtD) and/or lomitapide or a pharmaceutically-acceptable salt thereof. The uPtD and/or lomitapide can be encapsulated in a nanoparticle for administration to a subject. Some embodiments further include paclitaxel or a pharmaceutically-acceptable salt thereof.

A pharmaceutical composition comprising: a) an effective amount of an Inhibitors of Apoptosis Proteins (IAP) inhibitor, wherein the IAP inhibitor is represented by formula (I): or a pharmaceutically acceptable salt thereof, the definitions of each variable are provided herein; b) an effective amount of a second inhibitor, wherein the second inhibitor is a poly ADP ribose polymerase (PARP) inhibitor or a mitogen-activated protein kinase kinase (MEK) inhibitor; and a pharmaceutically acceptable carrier or diluent.

##STR00001##

A pharmaceutical composition comprising: a) an effective amount of an Inhibitors of Apoptosis Proteins (IAP) inhibitor, wherein the IAP inhibitor is represented by formula (I): or a pharmaceutically acceptable salt thereof, the definitions of each variable are provided herein; b) an effective amount of a second inhibitor, wherein the second inhibitor is a poly ADP ribose polymerase (PARP) inhibitor or a mitogen-activated protein kinase kinase (MEK) inhibitor; and a pharmaceutically acceptable carrier or diluent.

##STR00001##

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.

This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.

A balloon catheter is disclosed that can effectively deliver a drug to living body tissue, a method of manufacturing a balloon catheter, and a treatment method. A balloon catheter is disclosed, the balloon catheter is provided on an outer surface of a balloon with a plurality of elongate bodies which are independent crystals of a water-insoluble drug extending in an elongate form. The elongate bodies include fixed-side elongate bodies which are fixed to the outer surface side of the balloon, and top-side elongate bodies which are bent or broken from the fixed-side elongate bodies and are continuous with or independent of the fixed-side elongate bodies.